On that note, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) worked together to develop and commercialize their coronavirus vaccine, Comirnaty. In BioNTech's second quarter, practically 100% of its product sales, totaling around $3.3 billion, were attributable to its share of jab revenue.
Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.
Style Box ETF report for RDVY